The possible reasons might be that: (a) lnc‐ITSN1‐2 increased inflammation to result in an enhanced severity of AIS, finally causing worse RFS in AIS patients (abovementioned); (b) lnc‐ITSN1‐2 might activate or suppress several pathways to induce drug resistance, reducing treatment effect and causing worse RFS in AIS patients, while the underlying molecular mechanism needed further exploration. This evidence concerns the gene ITSN1 and androgen insensitivity syndrome.